Intravacc, a leader in translational research and the development of vaccines against infectious diseases and therapeutic vaccines, has launched its new hybrid business model that aims to lead to further innovation and sustainable growth over the next five years.
 
On the one hand, Intravacc’s new business model leans on contract research and small-scale GMP production for clinical research on vaccine efficacy and safety (CDMO), and on the other hand, it focuses on the independent development and commercialization of proprietary intranasally administered vaccine candidates through licensing agreements.
 
Potential of Intravacc’s Contract Research
 
Intravacc has signed a number of multi-year contracts with profit and non-profit organizations for the development of vaccines against both infectious diseases and cancer. These projects will generate revenue for Intravacc through licensing, technology, R&D services, and pilot production. A number of milestone and royalty contracts (approx. 3%) have been signed, which will run through 2031. Intravacc expects to enter into one to two service-, and partnership agreements per year, with income from these contracts accounting for 70-80% of the company’s total revenue.
 
Prior to its privatization on January 1 of this year, Intravacc was a governmental vaccine research institute with a rich pipeline of vaccine candidates against bacterial and viral infections. At the time, these vaccines, now part of Intravacc B.V., were developed on several patented platforms and the results of the relevant studies were published in leading scientific journals. The unique feature of these vaccines is their administration through the nose. These proprietary vaccines will be marketed under a partnership or licensing agreement, following completion of a phase I clinical trial. These proprietary vaccines will eventually contribute about 20% to Intravacc’s turnover.
 
Dr. Jan Groen, Intravacc’s CEO, said, “Our new hybrid business model makes Intravacc well positioned to capitalize on the rapidly growing market for therapeutic cancer vaccines.  Revenues derived from our contract research activities will form the basis of our revenue growth. Our proprietary pipeline of intranasal vaccines is also promising. Intravacc will initiate a financing round, possibly together with a partner, to enable the development of these vaccines up to clinical phase I.”